MX2012014479A - Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso. - Google Patents

Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.

Info

Publication number
MX2012014479A
MX2012014479A MX2012014479A MX2012014479A MX2012014479A MX 2012014479 A MX2012014479 A MX 2012014479A MX 2012014479 A MX2012014479 A MX 2012014479A MX 2012014479 A MX2012014479 A MX 2012014479A MX 2012014479 A MX2012014479 A MX 2012014479A
Authority
MX
Mexico
Prior art keywords
methods
salts
manufacture
amiodarone
formulations including
Prior art date
Application number
MX2012014479A
Other languages
English (en)
Inventor
Gerold L Mosher
Stephen Machatha
Daniel Cushing
Bushra Agha
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2012014479A publication Critical patent/MX2012014479A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención abarca formulaciones líquidas listas para administrarse incluyendo amiodarona y una ciclodextrina substituida. La invención también abarca métodos para hacer las formulaciones líquidas para proporcionar concentraciones aceptables de amiodarona adecuadas para administración parenteral. Las formulaciones líquidas de la invención son formulaciones incluidas, por ejemplo, en una bolsa, botella o jeringa intravenosa lista para usarse.
MX2012014479A 2010-06-11 2011-06-08 Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso. MX2012014479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35392710P 2010-06-11 2010-06-11
PCT/US2011/039617 WO2011156481A2 (en) 2010-06-11 2011-06-08 Formulations including amiodarone and salts thereof and methods of their manufacture and use

Publications (1)

Publication Number Publication Date
MX2012014479A true MX2012014479A (es) 2013-05-20

Family

ID=44514348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014479A MX2012014479A (es) 2010-06-11 2011-06-08 Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.

Country Status (9)

Country Link
US (1) US20120142768A1 (es)
EP (1) EP2579869A2 (es)
CN (1) CN103079559A (es)
AU (1) AU2011264919A1 (es)
BR (1) BR112012031504A2 (es)
CL (1) CL2012003488A1 (es)
MX (1) MX2012014479A (es)
WO (1) WO2011156481A2 (es)
ZA (1) ZA201300160B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014044972A1 (fr) * 2012-09-19 2014-03-27 Centre National De La Recherche Scientifique - Cnrs - Traitement des neuronopathies motrices
CN104887619A (zh) * 2014-03-04 2015-09-09 浙江普利药业有限公司 盐酸胺碘酮注射液及其制备方法
US9642828B2 (en) * 2014-09-23 2017-05-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of amiodarone
CN105708835A (zh) * 2014-12-04 2016-06-29 辽宁药联制药有限公司 门冬氨酸钾联合胺碘酮治疗室性心律失常
WO2017149552A1 (en) * 2016-03-04 2017-09-08 Sun Pharmaceutical Industries Ltd. Parenteral dosage form of amiodarone
CN107753439A (zh) * 2016-08-22 2018-03-06 黑龙江迪龙制药有限公司 一种注射用盐酸胺碘酮及其制备方法
US20220257537A1 (en) * 2021-02-15 2022-08-18 Sintetica S.A. Dilute ready to use large volume containers of phenylephrine
CN115969833A (zh) * 2023-01-03 2023-04-18 上海上药第一生化药业有限公司 胺碘酮药物组合物、注射液及其制备方法及含其的注射器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686125A (en) 1984-09-28 1987-08-11 Baxter Travenol Laboratories, Inc. Film laminate for sterile flexible containers
US4692361A (en) 1984-09-28 1987-09-08 Baxter Travenol Laboratories, Inc. Film laminate with gas barrier for sterile flexible containers
US4779997A (en) 1987-04-27 1988-10-25 Baxter Travenol Laboratories, Inc. Closure for a port and closure assembly
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5234949A (en) 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
FR2735978B1 (fr) 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
US20020143051A1 (en) 2001-03-29 2002-10-03 Doty Mark J. Premixed amiodarone parenteral solution and method for making the same
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
WO2011156481A3 (en) 2012-06-28
AU2011264919A1 (en) 2013-01-10
CN103079559A (zh) 2013-05-01
EP2579869A2 (en) 2013-04-17
WO2011156481A2 (en) 2011-12-15
US20120142768A1 (en) 2012-06-07
CL2012003488A1 (es) 2013-04-01
BR112012031504A2 (pt) 2016-11-08
ZA201300160B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2012014479A (es) Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.
PH12015500115B1 (en) Glucagon analogues
MX2015008066A (es) Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
NZ709958A (en) Enhanced stability of novel liquid compositions
MY188598A (en) Dexmedetomidine premix formulation
WO2013028942A8 (en) Targeting microbubbles
IN2014MN02214A (es)
EP4360621A3 (en) Formulations of bendamustine
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
MX337464B (es) Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.
IN2015DN02999A (es)
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
PH12015501313B1 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
PH12017501005A1 (en) Injectable formulations of paracetamol
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
UA99921U (ru) Способ контролируемой седации у пациентов с состоянием отмены алкоголя в отделении интенсивной терапии
MY187672A (en) Pharmaceutical preparation for anaesthetic use and associated preparation process
UA56353U (ru) Способ возобновления проходности слезоносового канала у детей с введением лекарственного средства
RU2012149676A (ru) Способ лечения телят, больных симулиидотоксикозом
UA69880U (ru) Способ премедикации у онкологических больных

Legal Events

Date Code Title Description
FA Abandonment or withdrawal